{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:53:33Z","timestamp":1779890013336,"version":"3.53.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neuropathic pain is a chronic and often disabling condition that remains refractory to monotherapy because of limited efficacy and dose-limiting adverse effects. Combination therapies that engage complementary mechanisms of action offer a rational strategy to enhance efficacy while minimizing toxicity. Pregabalin, a ligand of \u03b1<jats:sub>2<\/jats:sub>\u03b4 subunits of voltage-gated calcium channels, reduces presynaptic calcium influx and glutamate release. In contrast, thioctic acid (\u03b1-lipoic acid), a potent antioxidant with anti-inflammatory properties, modulates TRPV1 channel expression and activity and inhibits CaV3.2\u00a0T-type calcium channels. Both agents exert antiallodynic effects in preclinical models, yet their pharmacodynamic interaction has not been systematically evaluated. Given their distinct but convergent actions on neuronal excitability and pain signalling, quantitative synergy analysis is warranted to define the therapeutic potential of their combined use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We evaluated the antiallodynic efficacy of pregabalin and thioctic acid, alone and in combination, in female Wistar rats subjected to L5\u2013L6 spinal nerve ligation. Mechanical withdrawal thresholds were measured using von Frey filaments up to 8\u00a0h post-oral administration. Dose\u2013response curves were generated for each monotherapy and its 1:1 fixed-ratio combination. Isobolographic analysis was conducted to quantify pharmacodynamic interactions. All behavioural testing was performed under blinded conditions, and adverse effects were qualitatively monitored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Both compounds produced dose-dependent increases in mechanical withdrawal thresholds (antiallodynic effects), with ED<jats:sub>50<\/jats:sub> values of 2.45 \u00b1 0.23\u00a0mg\/kg for pregabalin and 57.49 \u00b1 5.59\u00a0mg\/kg for thioctic acid. The 1:1 fixed-ratio combination yielded an ED<jats:sub>50<\/jats:sub> of 15.7 \u00b1 1.0\u00a0mg\/kg and a maximal %MPE of 72.3% \u00b1 4.8%. Isobolographic analysis demonstrated a synergistic interaction, with an interaction index (\u03b3) of 0.524 (95% CI: 0.41\u20130.66; p &amp;lt; 0.05 vs. theoretical ED<jats:sub>50<\/jats:sub>). No overt adverse effects were observed at combination doses, whereas mild sedation occurred only at the highest pregabalin monotherapy dose.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These findings provide robust preclinical evidence that co-administration of pregabalin and thioctic acid produces synergistic antiallodynic effects in a validated model of neuropathic pain. This interaction enables effective analgesia at reduced doses, supporting a potential tolerability advantage. Our data support further investigation of this combination in chronic dosing paradigms, inclusion of both sexes, and clinical translation.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1675015","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:18:44Z","timestamp":1756711124000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Synergistic antiallodynic effects of pregabalin and thioctic acid in a rat model of neuropathic pain"],"prefix":"10.3389","volume":"16","author":[{"given":"Edith","family":"Z\u00e1rate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicio","family":"Granados-Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Arias-Carri\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1212\/01.CON.0000411564.41709.2d","article-title":"Neuropathic pain: mechanisms, therapeutic approach, and interpretation of clinical trials","volume":"18","author":"Attal","year":"2012","journal-title":"Continuum"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-540-79090-7_1","article-title":"Neuropathic pain: a clinical perspective","volume":"194","author":"Baron","year":"2009","journal-title":"Handb. Exp. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J. Neurosci. Methods"},{"key":"B4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/ddr.21473","article-title":"Antiallodynic interaction and motor performance of the pregabalin\/thioctic acid and pregabalin\/\u03b1-tocopherol combinations in neonatal streptozotocin-induced diabetic rats","volume":"79","author":"Cruz-Alvarez","year":"2018","journal-title":"Drug Dev. Res."},{"key":"B5","doi-asserted-by":"publisher","first-page":"CD007076","DOI":"10.1002\/14651858.CD007076.pub3","article-title":"Pregabalin for neuropathic pain in adults","volume":"1","author":"Derry","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.tins.2015.02.001","article-title":"Epigenetic mechanisms of chronic pain","volume":"38","author":"Descalzi","year":"2015","journal-title":"Trends Neurosci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.pain.2007.08.033","article-title":"Pharmacologic management of neuropathic pain: evidence-based recommendations","volume":"132","author":"Dworkin","year":"2007","journal-title":"Pain"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.amjmed.2009.04.005","article-title":"Revised definition of neuropathic pain and its grading system: an open case series illustrating its use in clinical practice","volume":"122","author":"Geber","year":"2009","journal-title":"Am. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/j.pain.0000000000003038","article-title":"Randomized, double-blind, controlled trial of a combination of alpha-lipoic acid and pregabalin for neuropathic pain: the PAIN-CARE trial","volume":"165","author":"Gilron","year":"2024","journal-title":"Pain"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.3390\/nu15163634","article-title":"Effects of oral alpha-lipoic acid treatment on diabetic polyneuropathy: a meta-analysis and systematic review","volume":"15","author":"Hsieh","year":"2023","journal-title":"Nutrients"},{"key":"B11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1177\/0300060515569287","article-title":"The effect of thioctic acid on allodynia in a rat vincristine-induced neuropathy model","volume":"43","author":"Kahng","year":"2015","journal-title":"J. Int. Med. Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.3390\/medicina61061063","article-title":"Evolving treatment strategies for neuropathic pain: a narrative review","volume":"61","author":"Kaye","year":"2025","journal-title":"Medicina"},{"key":"B13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0304-3959(92)90041-9","article-title":"An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat","volume":"50","author":"Kim","year":"1992","journal-title":"Pain"},{"key":"B14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.neuroscience.2008.02.031","article-title":"Pharmacological characterization and gene expression profiling of an L5\/L6 spinal nerve ligation model for neuropathic pain in mice","volume":"153","author":"Kiso","year":"2008","journal-title":"Neuroscience"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.3390\/ph17111538","article-title":"Effects of short-term treatment with \u03b1-lipoic acid on neuropathic pain and biomarkers of DNA damage in patients with diabetes mellitus","volume":"17","author":"Lazutka","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B16","doi-asserted-by":"publisher","first-page":"9500","DOI":"10.1523\/jneurosci.5803-08.2009","article-title":"Molecular mechanisms of lipoic acid modulation of T-type calcium channels in pain pathway","volume":"29","author":"Lee","year":"2009","journal-title":"J. Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1513597","DOI":"10.3389\/fpain.2024.1513597","article-title":"Pregabalin vs. gabapentin in the treatment of neuropathic pain: a comprehensive systematic review and meta-analysis of effectiveness and safety","volume":"5","author":"Mayoral","year":"2024","journal-title":"Front. Pain Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2165\/00044011-200828080-00004","article-title":"Thioctic acid and acetyl-L-carnitine in the treatment of sciatic pain caused by a herniated disc: a randomized, double-blind, comparative study","volume":"28","author":"Memeo","year":"2008","journal-title":"Clin. Drug Investig."},{"key":"B19","doi-asserted-by":"publisher","first-page":"456279","DOI":"10.1155\/2012\/456279","article-title":"Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials","volume":"2012","author":"Mijnhout","year":"2012","journal-title":"Int. J. Endocrinol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0022-510x(99)00017-9","article-title":"Alpha-lipoic acid provides neuroprotection from ischemia-reperfusion injury of peripheral nerve","volume":"163","author":"Mitsui","year":"1999","journal-title":"J. Neurological Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41583-020-0310-6","article-title":"Qualitative sex differences in pain processing: emerging evidence of a biased literature","volume":"21","author":"Mogil","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1517\/14656566.2014.972935","article-title":"Efficacy of \u03b1-lipoic acid in diabetic neuropathy","volume":"15","author":"Papanas","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.14193\/jkfas.2022.26.4.177","article-title":"Efficacy and safety of \u03b1-lipoic acid and low dose pregabalin combination in painful diabetic neuropathy","volume":"26","author":"Park","year":"2022","journal-title":"J. Korean Foot Ankle Soc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1517\/17425255.2013.749239","article-title":"Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy","volume":"9","author":"Schulze-Bonhage","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.bbagen.2009.07.026","article-title":"Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential","volume":"1790","author":"Shay","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1201\/9781420036107","volume-title":"Drug synergism and dose-effect data analysis","author":"Tallarida","year":"2000"},{"key":"B27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2174\/1570159x1201140117162802","article-title":"Pregabalin in neuropathic pain: evidences and possible mechanisms","volume":"12","author":"Verma","year":"2014","journal-title":"Curr. Neuropharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jpain.2013.02.011","article-title":"Descending facilitation maintains long-term spontaneous neuropathic pain","volume":"14","author":"Wang","year":"2013","journal-title":"J. Pain"},{"key":"B29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10863-023-09971-w","article-title":"Alpha-lipoic acid modulates the diabetes mellitus-mediated neuropathic pain via inhibition of the TRPV1 channel, apoptosis, and oxidative stress in rats","volume":"55","author":"Yaz\u011fan","year":"2023","journal-title":"J. Bioenergetics Biomembr."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1357859","DOI":"10.3389\/fendo.2024.1357859","article-title":"Combination therapy is it in the future for successfully treating peripheral diabetic neuropathy?","volume":"15","author":"Yorek","year":"2024","journal-title":"Front. Endocrinol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1002\/ar.22816","article-title":"Pregabalin alters nociceptive behavior and expression level of P2X3 receptor in the spinal dorsal horn in a rat model induced by chronic compression of the dorsal root ganglion","volume":"296","author":"Yu","year":"2013","journal-title":"Anat. Rec."},{"key":"B32","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1528-1167.2010.02966.x","article-title":"The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials","volume":"52","author":"Zaccara","year":"2011","journal-title":"Epilepsia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"117929","DOI":"10.1016\/j.biopha.2025.117929","article-title":"Pharmacological interactions of sulforaphane and gabapentin in a murine fibromyalgia-like pain model","volume":"184","author":"Zamora-Diaz","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"B34","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/cns.13303","article-title":"Alpha-lipoic acid downregulates TRPV1 receptor via NF-\u03baB and attenuates neuropathic pain in rats with diabetes","volume":"26","author":"Zhang","year":"2020","journal-title":"CNS Neurosci. and Ther."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.2337\/dc06-1216","article-title":"Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial","volume":"29","author":"Ziegler","year":"2006","journal-title":"Diabetes Care"},{"key":"B36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0304-3959(83)90201-4","article-title":"Ethical guidelines for investigations of experimental pain in conscious animals","volume":"16","author":"Zimmermann","year":"1983","journal-title":"Pain"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1675015\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:18:45Z","timestamp":1756711125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1675015\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":36,"alternative-id":["10.3389\/fphar.2025.1675015"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1675015","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"1675015"}}